Transform oncology with AI to fast-track life-saving treatments.
Inka Health is pioneering the use of advanced AI-driven analytics and real-world multimodal data to revolutionize clinical research and drug development.
We integrate cutting-edge technologies with rigorous methodologies to deliver actionable insights that drive innovation and precision in oncology.
Our commitment: empowering healthcare advancements with clarity and precision.
Leadership
Paul Arora, PhD
Chief Executive Officer
Paul Arora is CEO of Inka Health and an Adjunct Professor at the University of Toronto. He is an expert in epidemiology, specializing in real-world evidence, health outcomes, and causal inference. He has led numerous large-scale consulting projects. He previously founded Lighthouse Outcomes (acquired).
Alind Gupta, PhD
Chief Scientific Officer
Alind Gupta is CSO at Inka Health and an Adjunct Professor at the University of Toronto. He has deep technical expertise in advanced real-world evidence, AI and causal inference methods. He has led advanced analytics projects at a major US consultancy and is a globally referenced author in health technology assessment (HTA) guidance documents.
Winson Cheung, MD
Medical Advisor
Winson Y. Cheung is a Full Professor at the University of Calgary and an expert in medical oncology and real-world evidence. With 15+ years in cancer research, he has published over 300 scientific papers and secured over $20M in research funding, specializing in health outcomes and real-world evidence generation in oncology.
Steven Jones, PhD
Scientific Advisor
Steven Jones is Head of Bioinformatics and Co-Director of the Genome Sciences Centre in Vancouver, and Distinguished Scientist at the BC Cancer Research Institute. He is among the world’s most highly cited researchers in his field, with pioneering contributions to bioinformatics and cancer genomics.
Strategic Advisors
James Orbinski, MD
James is a globally renowned humanitarian, scholar, and Officer of the Order of Canada. He is the Founding Director of York University's Dahdaleh Institute for Global Health Research and former International Council President of Médecins Sans Frontières (Doctors Without Borders), where he accepted the Nobel Peace Prize on behalf of the organization in 1999.
Edward Mills, PhD
Ed Mills is the co-founder of MTEK Sciences and Redwood Outcomes, both successfully acquired by major industry players. He is a principal investigator of multiple adaptive platform trials and large-scale studies and has authored over 550 peer-reviewed papers in leading journals, including NEJM, The Lancet, and JAMA.
Kristian Thorlund, PhD
Kristian is the co-founder of Redwood Outcomes, MTEK Sciences (both acquired), and rAire, as well as the founder of Biospark.ai. A leading biostatistician specializing in Bayesian methods, he is a Clarivate Analytics Highly Cited Researcher, recognized for his impactful contributions to the field.
Our Strengths
Partnership
Enduring Relationships
Dedicated Partners
More than service providers, we commit to building long-term, sustainable relationships.
Customized Solutions
Tailoring our approach to meet the unique needs of each client.
Partner-Centric
Focused on delivering bespoke strategies that ensure collaborator satisfaction and success.
Confidence
Excellence in Methods
Superior Analytics
Instilling confidence with top-tier, transparent methods.
Evidence-Based
Leveraging ITC and real-world evidence for impactful insights.
Reliability & Impact
Ensuring our solutions are both dependable and effective.
Data Agnosticism
Flexible Strategies
Versatility in Data
A specialized approach means we can work with diverse data sources, ranging from RCTs to industry access programs.
​
High Standards
Transparency and rigor in all analytics processes.
Effective Handling
Ensuring adept management of various data types for comprehensive insights. We welcome any and all data provided by collaborators.
Innovation
Strategic Integration of AI
Innovative AI Use
Rooted in innovative, solution-oriented AI applications for analytics.
Focus on Causal Inference
Emphasizing the judicious use of AI to derive authentic insights from real-world data.
Distinctive Methods
Setting our approaches apart with advanced, credible analysis techniques.
Quality
Adherence to Best Practices
Strictly following the latest approaches in RWE and ITC, ensuring top-tier analytics quality.
Regulatory Alignment
In line with NICE, FDA, ISPOR, and CADTH guidelines for excellence in study design and reporting.
Quality Assurance
Commitment to the highest standards in all analytical processes.
Speed
Accelerated Analytics
Utilizing advanced automation for swift insights, delivering results in half the traditional time.
Investment in Innovation
Embracing automation and machine learning for efficient decision-making.
Impact on Healthcare
Ensuring timely decisions that significantly enhance patient outcomes.
Leadership
Thought Leadership
Boasting over 500 published scientific papers by our founding and advisory team.
Methodological Innovation
At the cutting edge with techniques like target trial emulation and Bayesian borrowing.
Accurate Insights
Providing reliable insights through advanced methodologies.
Collaborator Testimonials
"The team's profound understanding of intricacies surrounding real-world evidence and application of cutting-edge methodologies has greatly contributed to the field."
"Winson and team have always been my first port of call for invaluable guidance on implementing innovative methods to enhance the credibility and acceptance of real-world evidence (RWE). The team's profound understanding of the intricacies surrounding real-world evidence and application of cutting-edge methodologies has greatly contributed to the field, showing how RWE can meet the stringent standards set by HTA and payer stakeholders."
- Global Head Real-World Evidence & Market Access at a large-cap pharmaceutical company